Cathepsin B inhibition limits bone metastasis in breast cancer

Cancer Research

Volumn 72, Issue 5, 2012, Pages 1199-1209

  Withana, Nimali P ^a,b   Blum, Galia ^b,c   Sameni, Mansoureh ^d   Slaney, Clare ^a   Anbalagan, Arulselvi ^d   Olive, Mary B ^e   Bidwell, Bradley N ^a,b   Edgington, Laura ^c   Wang, Ling ^c   Moin, Kamiar ^e,f   Sloane, Bonnie F ^e,f   Anderson, Robin L ^a,b   Bogyo, Matthew S ^c   Parker, Belinda S ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; COLLAGEN TYPE 1; N (3 PROPYLCARBAMOYLOXIRANE 2 CARBONYL)ISOLEUCYLPROLINE; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BREAST CANCER; COLLAGEN DEGRADATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FLUORESCENCE IMAGING; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CATHEPSIN B; CELL LINE, TUMOR; DIPEPTIDES; GENE KNOCKDOWN TECHNIQUES; HUMANS; LEUCINE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C;

EID: 84863229642     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2759     Document Type: Article

References (50)

1. American Cancer Society. Cancer facts & figures 2010. 2010.
2. Turk V, Kos J, Turk B. Cysteine cathepsins (proteases)-on the main stage of cancer? Cancer Cell 2004;5:409-10. (Pubitemid 38610242)
3. Brix K, Dunkhorst A, Mayer K, Jordans S. Cysteine cathepsins: cellular roadmap to different functions. Biochimie 2008;90:194-207. (Pubitemid 351172569)
4. Conus S, Simon HU. Cathepsins: key modulators of cell death and inflammatory responses. Biochem Pharmacol 2008;76:1374-82.
5. Tardy C, Codogno P, Autefage H, Levade T, Andrieu-Abadie N. Lysosomes and lysosomal proteins in cancer cell death (new players of an old struggle). Biochim Biophys Acta 2006;1765:101-25.
6. Zavasnik-Bergant T, Turk B. Cysteine proteases: destruction ability versus immunomodulation capacity in immune cells. Biol Chem 2007;388:1141-9. (Pubitemid 350059624)
7. Troen BR. The role of cathepsin K in normal bone resorption. Drug News Perspect 2004;17:19-28. (Pubitemid 38419368)
8. Gocheva V, Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007;6:60-4. (Pubitemid 46173882)
9. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006;6:764-75. (Pubitemid 44450465)
10. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 2007;13:387-403. (Pubitemid 46477760)
11. Joyce JA, Hanahan D. Multiple roles for cysteine cathepsins in cancer. Cell Cycle 2004;3:1516-619.
12. Lankelma JM, Voorend DM, Barwari T, Koetsveld J, Van der Spek AH, De Porto AP, et al. Cathepsin L, target in cancer treatment? Life Sci 2010;86:225-33.
13. Jain M, Bakhshi S, Shukla AA, Chauhan SS. Cathepsins B and L in peripheral blood mononuclear cells of pediatric acute myeloid leukemia: potential poor prognostic markers. Ann Hematol 2010;89: 1223-32.
14. Lah TT, Kalman E, Najjar D, Gorodetsky E, Brennan P, Somers R, et al. Cells producing cathepsins D, B, and L in human breast carcinoma and their association with prognosis. Hum Pathol 2000;31:149-60. (Pubitemid 30090643)
15. Nouh MA, Mohamed MM, El-Shinawi M, Shaalan MA, Cavallo-Medved D, Khaled HM, et al. Cathepsin B: a potential prognostic marker for inflammatory breast cancer. J Transl Med 2011;9:1.
16. Vasiljeva O, Korovin M, Gajda M, Brodoefel H, Bojic L, Krüger A, et al. Reduced tumor cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. Oncogene 2008;27:4191-9. (Pubitemid 351969911)
17. Sevenich L, Werner F, Gajda M, Schurigt U, Sieber C, Müller S, et al. Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice. Oncogene 2010;30:54-64.
18. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004;5:443-53. (Pubitemid 38610246)
19. Bell-McGuinn KM, Garfall AL, Bogyo M, Hanahan D, Joyce JA. Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res 2007;67:7378-85. (Pubitemid 47206568)
20. Parker BS, Ciocca DR, Bidwell BN, Gago FE, Fanelli MA, George J, et al. Primary tumor expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer. J Pathol 2008;214:337-46. (Pubitemid 351212389)
21. Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, Tavaria MD, et al. Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res 2005;3:1-13. (Pubitemid 40189591)
22. Sinha AA, Quast BJ, Wilson MJ, Fernandes ET, Reddy PK, Ewing SL, et al. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma. Cancer 2002;94:3141-9. (Pubitemid 34670497)
23. Strojnik T, Zajc I, Bervar A, Zidanik B, Golouh R, Kos J, et al. Cathepsin B and its inhibitor stefin A in brain tumors. Pflugers Arch 2000;439(3 Suppl):R122-3.
24. Moin K, Day NA, Sameni M, Hasnain S, Hirama T, Sloane BF. Human tumor cathepsin B. Comparison with normal liver cathepsin B. Biochem J 1992;285 (Pt 2):427-34.
25. Cavallo-Medved D, Rudy D, Blum G, Bogyo M, Caglic D, Sloane BF. Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation. Exp Cell Res 2009;315:1234-46.
26. Jedeszko C, Sameni M, Olive MB, Moin K, Sloane BF. Visualizing protease activity in living cells: from two dimensions to four dimensions. Curr Protoc Cell Biol 2008;Chapter 4:Unit 4 20.
27. Sameni M, Cavallo-Medved D, Dosescu J, Jedeszko C, Moin K, Mullins SR, et al. Imaging and quantifying the dynamics of tumor-associated proteolysis. Clin Exp Metastasis 2009;26:299-309.
28. Blum G, von Degenfeld G, Merchant MJ, Blau HM, Bogyo M. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat Chem Biol 2007;3:668-77. (Pubitemid 47417706)
29. Berdowska I. Cysteine proteases as disease markers. Clin Chim Acta 2004;342:41-69. (Pubitemid 38352913)
30. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, et al. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 1999;17:163-70. (Pubitemid 29335443)
31. Murata M, Miyashita S, Yokoo C, Tamai M, Hanada K, Hatayama K, et al. Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro. FEBS Lett 1991;280:307-10.
32. Meara JP, Rich DH. Mechanistic studies on the inactivation of papain by epoxysuccinyl inhibitors. J Med Chem 1996;39:3357-66. (Pubitemid 26322861)
33. Schurigt U, Sevenich L, Vannier C, Gajda M, Schwinde A, Werner F, et al. Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model. Biol Chem 2008;389:1067-74.
34. Matarrese P, Ascione B, Ciarlo L, Vona R, Leonetti C, Scarsella M, et al. Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study. Mol Cancer 2010; 9:207.
35. Qian J, Bostwick DG, Iczkowski KA, Betre K, Wilson MJ, LE C, et al. Characterization of prostate cancer in needle biopsy by cathepsin B, cell proliferation and DNA ploidy. Anticancer Res 2010;30:719-25.
36. Buck MR, Karustis DG, Day NA, Honn KV, Sloane BF. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumor tissues. Biochem J 1992;282 (Pt 1):273-8.
37. Premzl A, Zavasnik-Bergant V, Turk V, Kos J. Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp Cell Res 2003;283:206-14. (Pubitemid 36269026)
38. Podgorski I, Linebaugh BE, Sameni M, Jedeszko C, Bhagat S, Cher ML, et al. Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer. Neoplasia 2005;7:207-23. (Pubitemid 40411633)
39. Vasiljeva O, Papazoglou A, Krüger A, Brodoefel H, Korovin M, Deussing J, et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res 2006;66:5242-50. (Pubitemid 43844948)
40. Campo E, Muñoz J, Miquel R, Palacín A, Cardesa A, Sloane BF, et al. Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am J Pathol 1994;145: 301-9. (Pubitemid 24245830)
41. Fernández PL, Farré X, Nadal A, Fernández E, Peiró N, Sloane BF, et al. Expression of cathepsins B and S in the progression of prostate carcinoma. Int J Cancer 2001;95:51-5.
42. Le Gall C, Bellahcène A, Bonnelye E, Gasser JA, Castronovo V, Green J, et al. A cathepsin k inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 2007;67:9894-902. (Pubitemid 47621238)
43. Wilson TJ, Nannuru KC, Futakuchi M, Sadanandam A, Singh RK. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand. Cancer Res 2008;68:5803-11.
44. Benavides F, Perez C, Blando J, Contreras O, Shen J, Coussens LM, et al. Protective role of cathepsin L in mouse skin carcinogenesis. Mol Carcinog 2011. Epub 2011 May 2.
45. Fingleton B. Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects. Expert Opin Ther Targets 2003;7:385-97. (Pubitemid 36722223)
46. Overall CM, Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 2006;94:941-6.
47. Papachristou DJ, Basdra EK, Papavassiliou AG. Bone metastases: molecular mechanisms and novel therapeutic interventions. Med Res Rev 2010. Epub 2011 Sep 3.
48. Salminen-Mankonen HJ, Morko J, Vuorio E. Role of cathepsin K in normal joints and in the development of arthritis. Curr Drug Targets 2007;8:315-23.
49. Lindeman JH, Hanemaaijer R, Mulder A, Dijkstra PD, Szuhai K, Bromme D, et al. Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol 2004;165:593-600. (Pubitemid 38971388)
50. Bromme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs 2009;18:585-600.